A Phase Ib Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Continuous Dosing With BIBW 2992 Combined With Two Different Regimens of Backbone Chemotherapy: Cisplatin Combined With 5 Fluorouracil and Cisplatin Combined With Paclitaxel in Patients With Advanced Solid Tumours.

Trial Profile

A Phase Ib Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Continuous Dosing With BIBW 2992 Combined With Two Different Regimens of Backbone Chemotherapy: Cisplatin Combined With 5 Fluorouracil and Cisplatin Combined With Paclitaxel in Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2013

At a glance

  • Drugs Afatinib (Primary) ; Cisplatin; Fluorouracil; Paclitaxel
  • Indications Cervical cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 14 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Planned number of patients changed from 48 to 47 as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Planned end date changed from 1 Dec 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top